Advanced Molecular Imaging with anti-3[18F] FACBC to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy

Prostate cancer is the most common solid tumor, with approximately 200,000 new cases diagnosed per year. Several different local therapies are available for treatment, including prostatectomy, cryotherapy and radiotherapy. The differentiation of local from regional or distant recurrence is of critical importance in decisions regarding treatment modality in patients with recurrent prostate cancer.   The overall goal of this study is to improve the long term biochemical free survival of patients with recurrent prostate carcinoma by altering the current decision algorithm through the ability of advanced molecular imaging to guide the appropriate selection of patients who will benefit from salvage radiotherapy.

We plan to leverage advanced molecular imaging with the positron emission tomography (PET) radiotracer anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-3-[18F]FACBC), which in preliminary data is able to differentiate prostatic from extra-prostatic recurrence even at low PSA levels. Doing so will enable more appropriate selection of patients who will benefit from salvage radiotherapy and to achieve durable response at higher PSA levels than previously believed.


Funding Agency: National Institutes of Health
PI: Ashesh Jani, MD and David M Schuster, MD
Grant Type: R01 CA169188-01
Funding Period: 9/01/12-6/30/17

For further information about this study